Dateline City: NEWTON, Mass. NEWTON, Mass.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, announced it completed the enrollment phase of the Tryton First-in-Man (FIM) Study. The multi-center clinical trial evaluated the safety of Tryton’s Side-Branch Stent in the treatment of coronary bifurcation lesions. The Study was performed at the: HELIOS Heart Center/Siegburg, Germany (Prof. …
Tryton Medical, Inc. Announces First Clinical Use Of Its Side-Branch Stent™ To Treat Coronary Bifurcation Lesions
Dateline City: BOSTON BOSTON–(BUSINESS WIRE)–Tryton Medical, Inc. announced today the first clinical use of its Tryton Side-Branch Stent (TM). The initial cases were performed at the Heart Center/Siegburg under the direction of Professor Eberhard Grube, M.D. “These cases demonstrate that a Tryton stent strategy provides a simple and easy way to treat complex bifurcation lesions with beautiful results,” according to …